Mesoblast Ltd banner

Intrinsic Value

The intrinsic value of Mesoblast Ltd (MEOBF) under the Base Case is 1.13 USD per share. Compared with the current market price of 1.53 USD, the stock appears Overvalued by 26% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

MEOBF Intrinsic Value
$1.13
Overvaluation 26%
Intrinsic Value
Price $1.53

We don’t have enough historical valuation data to make this comparison.

Monitor MEOBF
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $0.9
Get notified when the price drops into your buy zone
Current Price $1.53
Intrinsic Value $1.13
Margin of Safety 20% $0.9
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to MEOBF

Fundamental Analysis

What Mesoblast Does

Biotechnology Health Care

Mesoblast is a biotechnology company that develops cell-based medicines, especially treatments made from donated adult stem cells. Its main work is to research, test, and seek approval for therapies aimed at hard-to-treat inflammatory and immune-related diseases, as well as some serious spine and heart conditions.

Headquarters
Australia AU
Employees
81
IPO date
Dec 16, 2004
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Mesoblast Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one MEOBF stock?

The intrinsic value for Mesoblast Ltd (MEOBF) under the Base Case is 1.13 USD.

Is MEOBF stock undervalued or overvalued?

Compared with the current market price of 1.53 USD, the stock appears Overvalued by 26% .

Back to Top